Clinical Trial Update: Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer [Phase 1, Phase 2]

View source ↗

Summary

Withdrawal of a Phase 1/2 trial evaluating adding ASTX660 (tolinapant) to paclitaxel with or without bevacizumab in patients with recurrent ovarian, fallopian t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• ASTX660
• Bevacizumab (bevacizumab)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma | Phase 1, Phase 2 | Status: WITHDRAWN